ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative) |
Jun. 11, 2020
USD ($)
$ / shares
shares
|
|---|---|
| Assignment and Assumption Agreement [Member] | |
| Asset Acquisition [Line Items] | |
| Payment for purchase of assets | $ 250,241 |
| Trigemina Inc [Member] | Asset Purchase Agreement [Member] | |
| Asset Acquisition [Line Items] | |
| Payment for purchase of assets | $ 824,759 |
| Number of shares issued (in shares) | shares | 10,000 |
| Common stock value (per share) | $ / shares | $ 136.00 |
| Research and development costs | $ 2,400,000 |
| X | ||||||||||
- Definition The element represents common stock value per shares. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|